Dactolisib

N/A

Report date: 2024/12/02 20:00:42
NME

Base Information

Drug NameDactolisib
Drug Alias Name达托利司Dactolisibum达托利塞BEZ-235RTB-101 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase gamma inhibitors +[6] 
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2Phosphatidylinositol 3 kinase beta +[6] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Pancreatic neuroendocrine tumors (pNET)Metastatic breast cancer +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesRestorbio Inc
Inactive CompaniesCliniques Universitaires Saint-Luc A.S.B.L.Novartis Pharma AgGoethe University +[5] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Tract Infections
Inactive IndicationsPancreatic neuroendocrine tumors (pNET)Metastatic breast cancerSolid tumours +[16] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG